<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: ocata_10q%2D20150630.xfr; Date: 2015%2D08%2D05T14:13:53 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000004 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:OCAT="http://ocata.com/20150630">
    <link:schemaRef xlink:href="ocat-20150630.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_StockPlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCAT:StockPlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_StockPlan2005Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCAT:StockPlan2005Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_StockPlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCAT:StockPlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_StockPlan2005Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCAT:StockPlan2005Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">OCAT:LincolnParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_SecCivilActionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">OCAT:SecCivilActionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_SecCivilActionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">OCAT:SecCivilActionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_SecSectionInvestigationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">OCAT:SecSectionInvestigationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_SecSectionInvestigationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">OCAT:SecSectionInvestigationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_BoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">OCAT:BoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_OfficeFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">OCAT:OfficeFurnitureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_WarrantDerivativeLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantDerivativeLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantAndOptionDerivativeLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantAndOptionDerivativeLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantAndOptionDerivativeLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantAndOptionDerivativeLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_SCRMIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCAT:SCRMIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_SCRMIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCAT:SCRMIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_custom_SCRMIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCAT:SCRMIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_SCRMIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCAT:SCRMIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_CapitalLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">OCAT:CapitalLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_WarrantLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_custom_WarrantOverallotmentLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantOverallotmentLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_CapitalLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">OCAT:CapitalLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_CapitalLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">OCAT:CapitalLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_WarrantLiabilitiesMember434090222">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_WarrantLiabilitiesMember434090254">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_WarrantOverallotmentLiabilitiesMember434130174">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantOverallotmentLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_WarrantOverallotmentLiabilitiesMember434130174">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001140098</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">OCAT:WarrantOverallotmentLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">2245381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-06-30_custom_StockPlan2014Member" unitRef="Shares" decimals="INF">174000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-06-30_custom_StockPlan2005Member" unitRef="Shares" decimals="INF">2118931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">2292931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-06-30" unitRef="Shares" decimals="INF">2292931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-2735545</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">16185964</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">34620</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">42158</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">346364060</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">379559411</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-349134225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-363415605</us-gaap:StockholdersEquity>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1731202</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2014-12-31_custom_SecCivilActionMember" unitRef="USD" decimals="0">1356202</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2015-06-30_custom_SecCivilActionMember" unitRef="USD" decimals="0">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2014-12-31_custom_SecSectionInvestigationMember" unitRef="USD" decimals="0">375000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2015-06-30_custom_SecSectionInvestigationMember" unitRef="USD" decimals="0">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-06-30" unitRef="Shares" decimals="INF">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">34620218</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-06-30" unitRef="Shares" decimals="INF">42158214</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">34620218</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-06-30" unitRef="Shares" decimals="INF">42158214</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2015-07-31" unitRef="Shares" decimals="INF">42225714</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-24207750</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-14281380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-14281380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-7245810</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-15517976</us-gaap:NetIncomeLoss>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2015-01-01to2015-06-30_us-gaap_LeaseholdImprovementsMember">Lesser of remaining lease life or economic life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2015-01-01to2015-06-30_custom_CapitalLeasesMember">Lesser of lease life or economic life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2015-01-01to2015-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">5985000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2015-01-01to2015-06-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-06-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">6.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2015-01-01to2015-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">15000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">85725</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-01-01to2015-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-01-01to2015-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">85710</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2015-01-01to2015-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">99000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2015-01-01to2015-06-30_custom_StockPlan2014Member" unitRef="Shares" decimals="INF">209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2015-01-01to2015-06-30_custom_StockPlan2005Member" unitRef="Shares" decimals="INF">2756356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2015-01-01to2015-06-30" unitRef="Shares" decimals="INF">2965356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2014-01-01to2014-06-30" unitRef="Percent" decimals="INF">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2015-01-01to2015-06-30" unitRef="Percent" decimals="INF">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2014-01-01to2014-06-30" unitRef="Percent" decimals="INF">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2015-01-01to2015-06-30" unitRef="Percent" decimals="INF">.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2014-01-01to2014-06-30" unitRef="Percent" decimals="INF">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2015-01-01to2015-06-30" unitRef="Percent" decimals="INF">0.0207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2014-01-01to2014-06-30" unitRef="Percent" decimals="INF">0.0002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2015-01-01to2015-06-30" unitRef="Percent" decimals="INF">.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">10827517</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">10827517</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">11442052</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">11442052</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2015-06-30_custom_WarrantLiabilitiesMember434090222" unitRef="USD" decimals="0">10827517</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2014-12-31_custom_WarrantLiabilitiesMember434090254" unitRef="USD" decimals="0">16255</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2014-12-31_custom_WarrantOverallotmentLiabilitiesMember434130174" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2015-06-30_custom_WarrantOverallotmentLiabilitiesMember434130174" unitRef="USD" decimals="0">614535</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="From2015-01-01to2015-06-30_custom_WarrantDerivativeLiabilitiesMember" unitRef="USD" decimals="0">-343741</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="From2015-01-01to2015-06-30_custom_WarrantLiabilitiesMember" unitRef="USD" decimals="0">329509</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="From2015-01-01to2015-06-30_custom_WarrantOverallotmentLiabilitiesMember" unitRef="USD" decimals="0">14232</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantAndOptionDerivativeLiabilitiesMember" unitRef="USD" decimals="0">11442052</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4325886</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">31601475</us-gaap:CashUninsuredAmount>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2015-01-01to2015-06-30_us-gaap_MachineryAndEquipmentMember">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2015-01-01to2015-06-30_us-gaap_ComputerEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2015-01-01to2015-06-30_custom_OfficeFurnitureMember">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2015-01-01to2015-06-30_us-gaap_WarrantMember">P5Y5M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2015-01-01to2015-06-30_us-gaap_RestrictedStockUnitsRSUMember">P2Y2M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P1Y5M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember">P2Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-06-30_us-gaap_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-06-30_us-gaap_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-06-30_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-06-30_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:FairValueMeasurementsSignificantAssumptions contextRef="From2015-01-01to2015-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantAndOptionDerivativeLiabilitiesMember">Expected volatility of the Company's common stock</us-gaap:FairValueMeasurementsSignificantAssumptions>
    <us-gaap:FairValueMeasurementsChangesInSignificantAssumptions contextRef="From2015-01-01to2015-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantAndOptionDerivativeLiabilitiesMember">45% - 93%</us-gaap:FairValueMeasurementsChangesInSignificantAssumptions>
    <dei:EntityRegistrantName contextRef="From2015-01-01to2015-06-30">Ocata Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2015-01-01to2015-06-30">0001140098</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2015-01-01to2015-06-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2015-01-01to2015-06-30">2015-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2015-01-01to2015-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2015-01-01to2015-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2015-01-01to2015-06-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2015-01-01to2015-06-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2015-01-01to2015-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2015-01-01to2015-06-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2015-01-01to2015-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2015-01-01to2015-06-30">2015</dei:DocumentFiscalYearFocus>
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">34620218</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2015-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">42158214</us-gaap:SharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">2915701</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2915701</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">262877</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2015-01-01to2015-06-30_custom_BoardMember" unitRef="USD" decimals="0">85725</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-142734</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-85725</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:FairValueMeasurementsValuationTechniques contextRef="From2015-01-01to2015-06-30_us-gaap_FairValueInputsLevel3Member_custom_WarrantAndOptionDerivativeLiabilitiesMember">Black Scholes Model</us-gaap:FairValueMeasurementsValuationTechniques>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">5800000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2015-01-01to2015-06-30_custom_SCRMIMember" unitRef="USD" decimals="0">14706</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2014-01-01to2014-06-30_custom_SCRMIMember" unitRef="USD" decimals="0">14706</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">7353</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">7353</us-gaap:LicenseAndServicesRevenue>
    <OCAT:UnamortizedLicenseFee contextRef="AsOf2015-06-30_custom_SCRMIMember" unitRef="USD" decimals="0">307598</OCAT:UnamortizedLicenseFee>
    <OCAT:UnamortizedLicenseFee contextRef="AsOf2014-12-31_custom_SCRMIMember" unitRef="USD" decimals="0">322304</OCAT:UnamortizedLicenseFee>
    <us-gaap:VariableInterestEntityOwnershipPercentage contextRef="From2015-01-01to2015-06-30_custom_SCRMIMember" unitRef="Percent" decimals="INF">.40</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">663000</us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-06-30" unitRef="Percent" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-06-30" unitRef="Percent" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-06-30" unitRef="USDPShares" decimals="INF">7.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-06-30" unitRef="USDPShares" decimals="INF">5.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">6176415</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2015-01-01to2015-06-30">P2Y2M27D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:Assets contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">5737484</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">33338505</us-gaap:Assets>
    <us-gaap:OtherAssets contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">47707</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">39795</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">107779</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">76561</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4749035</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">32333654</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">324661</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">482079</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">5737484</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">33338505</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-349134225</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">-363415605</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">346364060</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">379559411</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">34620</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">42158</us-gaap:CommonStockValue>
    <us-gaap:Liabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">8473029</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">17152541</us-gaap:Liabilities>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1591826</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">1512890</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1188874</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">0</us-gaap:OtherLiabilities>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">16255</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">10827517</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">5676074</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">4766440</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">157873</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">157873</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2515674</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">2030534</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1271325</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">1942381</us-gaap:AccountsPayableCurrent>
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">47720</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">47718</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">23859</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">23861</us-gaap:GrossProfit>
    <us-gaap:CostOfRevenue contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">31217</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">31218</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">15609</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">15608</us-gaap:CostOfRevenue>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-06-30" unitRef="USDPShares" decimals="INF">-0.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-06-30" unitRef="USDPShares" decimals="INF">-0.4</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-04-01to2015-06-30" unitRef="USDPShares" decimals="INF">-0.2</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-04-01to2014-06-30" unitRef="USDPShares" decimals="INF">-0.55</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-06-30" unitRef="Shares" decimals="INF">28450663</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-06-30" unitRef="Shares" decimals="INF">35759552</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-04-01to2015-06-30" unitRef="Shares" decimals="INF">36566842</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-04-01to2014-06-30" unitRef="Shares" decimals="INF">29554577</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-25424745</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-14281380</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-7245810</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-16111167</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">1216995</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">593191</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-24207750</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-14281380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-7245810</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-15517976</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-72142</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-560885</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-566888</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">919546</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">676800</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">343741</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">337738</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">389771</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-18959</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-1004867</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-394237</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-343511</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">429504</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">437</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">437</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">132532</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">55840</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">951</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-24135608</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-13720495</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-6678922</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-16437522</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">24183328</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">13768213</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">6702781</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">16461383</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">5488312</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">6846760</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">3158901</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">2175749</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">5226469</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">6921453</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">3543880</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">2718625</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-10572936</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-13694411</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-852615</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-2734160</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-642256</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">149506</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:OtherNoncashExpense contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">18223</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">727844</us-gaap:OtherNoncashExpense>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">65903</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:RecognitionOfDeferredRevenue contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">78937</us-gaap:RecognitionOfDeferredRevenue>
    <us-gaap:RecognitionOfDeferredRevenue contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">78936</us-gaap:RecognitionOfDeferredRevenue>
    <us-gaap:AmortizationOfDeferredCharges contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">31217</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">31218</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:Depreciation contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">64342</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">132824</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">67680</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">33382</us-gaap:Depreciation>
    <OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementAmount contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">25977600</OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementAmount>
    <OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementAmount contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementAmount>
    <OCAT:AccretionOfNoteReceivableDiscountOnPreferredStock contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">1153738</OCAT:AccretionOfNoteReceivableDiscountOnPreferredStock>
    <OCAT:AccretionOfNoteReceivableDiscountOnPreferredStock contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</OCAT:AccretionOfNoteReceivableDiscountOnPreferredStock>
    <OCAT:AccruedDividendsOnSeriesBAndCPreferredStock contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">1216995</OCAT:AccruedDividendsOnSeriesBAndCPreferredStock>
    <OCAT:AccruedDividendsOnSeriesBAndCPreferredStock contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</OCAT:AccruedDividendsOnSeriesBAndCPreferredStock>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">100724</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">437</us-gaap:InterestPaidNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4424374</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1743485</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">31851575</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2014-06-30" unitRef="USD" decimals="0">4062330</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">2318845</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">27427201</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">13011166</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">41241458</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">14281295</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">41243157</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-119385</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">-119846</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">119385</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">119846</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:CapitalLeaseObligations contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:CapitalLeaseObligations>
    <us-gaap:CapitalLeaseObligations contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">45694</us-gaap:CapitalLeaseObligations>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">21117</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-70129</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="From2015-01-01to2015-06-30_custom_WarrantLiabilitiesMember" unitRef="USD" decimals="0">11140771</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="From2015-01-01to2015-06-30_custom_WarrantOverallotmentLiabilitiesMember" unitRef="USD" decimals="0">628767</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:LicensesRevenue contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">78937</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">78936</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">39468</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">39469</us-gaap:LicensesRevenue>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-06-30" unitRef="Shares" decimals="INF">1330357</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-06-30" unitRef="Shares" decimals="INF">5834337</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1965567</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_us-gaap_MachineryAndEquipmentMember" unitRef="USD" decimals="0">1186232</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-06-30_us-gaap_MachineryAndEquipmentMember" unitRef="USD" decimals="0">1305078</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">104857</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-06-30_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">104857</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">54226</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-06-30_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">54226</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">620252</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-06-30_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">620252</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">2152923</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-06-30_custom_CapitalLeasesMember" unitRef="USD" decimals="0">68510</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_custom_CapitalLeasesMember" unitRef="USD" decimals="0">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1132604</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">1264428</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">832963</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">888495</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RepaymentsOfDebt contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">45906</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2015-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">6030906</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2015-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">45906</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">40.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <OCAT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2015-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">40.46</OCAT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <OCAT:WarrantsWeightedAverageRemainingContractualLifeExercisable contextRef="From2015-01-01to2015-06-30_us-gaap_WarrantMember">P11M16D</OCAT:WarrantsWeightedAverageRemainingContractualLifeExercisable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2015-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2015-01-01to2015-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="From2015-01-01to2015-06-30_custom_BoardMember" unitRef="Shares" decimals="INF">15000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2015-06-30_custom_StockPlan2014Member" unitRef="Shares" decimals="INF">41000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2015-06-30_custom_StockPlan2005Member" unitRef="Shares" decimals="INF">3231457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2015-06-30" unitRef="Shares" decimals="INF">3272457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2015-06-30_custom_StockPlan2014Member" unitRef="Shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2015-06-30_custom_StockPlan2005Member" unitRef="Shares" decimals="INF">5818388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2015-06-30" unitRef="Shares" decimals="INF">6068388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">2173329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">12.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">11.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">6.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">17.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-06-30_us-gaap_StockOptionMember">P7Y8M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_us-gaap_StockOptionMember">P8Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2014-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">12110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2015-01-01to2015-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">51450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2015-01-01to2015-06-30_us-gaap_StockOptionMember">P6Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2015-01-01to2015-06-30_us-gaap_StockOptionMember">P7Y7M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">493000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2015-06-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">503000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2015-06-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">566026</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">2915701</us-gaap:ShareBasedCompensation>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&lt;b&gt;Organization&#13;and Nature of Business&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Ocata&#13;Therapeutics, Inc., and Subsidiary (the &amp;#147;Company&amp;#148;) is a clinical stage biotechnology company focused on the development&#13;and commercialization of Regenerative Ophthalmology&lt;sup&gt;TM&lt;/sup&gt;&amp;#160;therapeutics. The most advanced products are in clinical&#13;trials for the treatment of Stargardt&amp;#146;s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration.&#13;The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular&#13;disorders. Additionally, the Company has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology,&#13;including autoimmune, inflammatory and wound healing-related disorders. The Company&amp;#146;s intellectual property portfolio includes&#13;pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy technologies.&#13;The Company has no therapeutic products currently available for sale and does not expect to have any therapeutic products commercially&#13;available for sale for a period of years, if at all. These factors indicate that the Company&amp;#146;s ability to continue research&#13;and development activities is dependent upon the ability of management to obtain additional financing as required.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company pursues a number of approaches to generating transplantable tissues both in-house and through collaborations with other&#13;researchers who have particular interests in, and skills related to, cellular differentiation. The Company&amp;#146;s research in&#13;this area includes projects focusing on the development of many different cell types that may be used to treat a range of diseases&#13;within ophthalmology and other therapeutic areas. Control of cellular differentiation and the culture and growth of stem and differentiated&#13;cells are important areas of research and development for the Company. Based on the success to date of the Phase 1 clinical trials&#13;and what the Company sees as favorable market dynamics of the ophthalmology sector, the Company has shifted its strategic priorities&#13;to focus primarily on the development, and ultimate commercialization of ophthalmology therapies. The largest indication involving&#13;macular degeneration is &amp;#147;age-related macular degeneration,&amp;#148; or AMD. AMD is the leading cause of blindness and visual&#13;impairment in adults over fifty years of age. The Company is also pursuing a treatment for Stargardt&amp;#146;s Macular Degeneration,&#13;or SMD, an inherited juvenile onset form of macular degeneration. The Company plans to initiate the Phase 2 clinical trial for&#13;dry AMD in the second half of this year.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company follows accounting standards set by the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;). The accompanying&#13;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#13;States of America, GAAP. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification,&amp;#153;&#13;sometimes referred to as the Codification or &amp;#147;ASC.&amp;#148; Although the Company believes that the disclosures in these financial&#13;statements are adequate to make the information presented not misleading, certain information normally included in the footnotes&#13;prepared in accordance with GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission&#13;(&amp;#147;SEC&amp;#148;).&amp;#160; The accompanying financial statements should be read in conjunction with the audited financial statements&#13;and notes thereto included in the Company&amp;#146;s Annual Report on Form 10&amp;#8722;K for the fiscal year ended December 31, 2014&#13;filed with the SEC on March 16, 2015.&amp;#160; The results for the three and six month periods ended June 30, 2015 are not necessarily&#13;indicative of the results that may be expected for the fiscal year ending December 31, 2015, or any future period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;accompanying consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the&#13;Company as a going concern. Management&amp;#146;s plans to continue as a going concern contemplate raising additional capital including&#13;the execution of an underwritten secondary offering completed in the second quarter of 2015 that resulted in approximately $28.4&#13;million in net proceeds, and the prior execution of an agreement for a $30 million equity line in late June 2014, of which approximately&#13;$5.8 million remains available as of June 30, 2015. The Company believes that its current cash balance, and the $5,822,405 available&#13;under the Lincoln Park financing arrangement as of June 30, 2015, will be sufficient to fund operations into the second half of&#13;2016. There can be no assurances that management can raise the necessary additional capital on favorable terms or at all. The accompanying&#13;financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The accounts of the Company and its wholly-owned subsidiary Mytogen,&amp;#160;Inc. are included in the accompanying consolidated financial&#13;statements. All intercompany balances and transactions were eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Segment Reporting&amp;#160;&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#151;&#13;ASC 280,&amp;#160;&lt;/font&gt;Segment Reporting&lt;font style="font-style: normal"&gt;&amp;#160;requires use of the &amp;#147;management approach&amp;#148;&#13;model for segment reporting. The management approach model is based on the way a company&amp;#146;s management organizes segments&#13;within the company for making operating decisions and assessing performance. The Company determined it has one operating segment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;These consolidated financial statements have been prepared in accordance with GAAP and, accordingly, require management to make&#13;estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and&#13;the reported amounts of revenues and expenses during the reporting period. In addition, management has estimated variables used&#13;to calculate the Black-Scholes option pricing model used to value derivative instruments, including outstanding warrants. Also,&#13;management has estimated the expected economic life and value of the Company&amp;#146;s licensed technology, the Company&amp;#146;s net&#13;operating loss for tax purposes, share-based payments for compensation to employees, directors, consultants and investment banks,&#13;and the useful lives of the Company&amp;#146;s fixed assets. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Certain prior period financial statement balances have been reclassified to conform to the current period presentation. Items include&#13;the presentation of net loss applicable to common stock and net loss applicable to common share on the face of the statement of&#13;operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Cash equivalents are comprised of certain highly liquid investments with maturities of three months or less when purchased. The&#13;Company maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. The Company has not experienced&#13;any losses related to this concentration of risk. As of June 30, 2015 and December 31, 2014, the Company had deposits in excess&#13;of federally-insured limits totaling $31,601,475 and $4,325,886, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Commitments and Contingencies&amp;#160;&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#151;&#13;The Company recognizes liabilities for contingencies and commitments when a loss is probable and can be reasonably estimated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Relating&#13;to loss contingencies the Company accrues the best estimate of a loss within a range. If no estimate in a range is better than&#13;any other, the minimum amount is accrued. The Company discloses a reasonably possible loss in excess of the amount accrued, if&#13;applicable. For reasonably possible loss contingencies, the Company discloses the nature of the loss contingency and provides a&#13;range of the estimate of possible loss or state that an estimate cannot be made.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Included&#13;in the other liabilities balance as of December 31, 2014 is approximately $1,200,000, primarily related to the acquisition of Mytogen&#13;which the Company did not expect to settle during 2015. This balance was reclassified to the accounts payable balance as of June&#13;30, 2015 as the Company expects to settle within the coming year.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Grants Receivable&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company periodically assesses its grants receivable for collectability on a specific identification basis. If collectability&#13;of an account becomes unlikely, the Company records an allowance for that doubtful account. Once the Company has exhausted efforts&#13;to collect, management writes off the grants receivable against the allowance it has already created.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company records its property and equipment at historical cost. The Company expenses maintenance and repairs as incurred. Upon&#13;disposition of property and equipment, the gross cost and accumulated depreciation are written off and the difference between the&#13;proceeds and the net book value is recorded as a gain or loss on sale of assets. In the case of certain assets acquired under capital&#13;leases, the assets are recorded net of imputed interest, based upon the net present value of future payments. Assets under capital&#13;lease are pledged as collateral for the related lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company provides for depreciation over the assets&amp;#146; estimated useful lives as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 30%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Machinery &amp;#38; equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 69%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Office furniture&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Lesser of remaining lease life or economic life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Capital leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Lesser of lease life or economic life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company follows ASC 350-30,&amp;#160;&lt;/font&gt;General Intangibles Other than Goodwill&amp;#160;&lt;font style="font-style: normal"&gt;(&amp;#147;ASC&#13;350-30&amp;#148;), in accounting for its patents. ASC 350-30 provides that costs of internally developing, maintaining, or restoring&#13;intangible assets that are not specifically identifiable, that have indeterminate lives, or that are inherent in a continuing business&#13;and related to an entity as a whole, shall be recognized as an expense when incurred. The Company has expensed as research and&#13;development expense all costs associated with developing its patents.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Equity Method Investment&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company follows ASC 323,&amp;#160;&lt;/font&gt;Investments-Equity Method and Joint Ventures,&amp;#160;&lt;font style="font-style: normal"&gt;in&#13;accounting for its investment in the joint venture. In the event the Company&amp;#146;s share of the joint venture&amp;#146;s net losses&#13;reduces the Company&amp;#146;s investment to zero, the Company will discontinue applying the equity method and will not provide for&#13;additional losses unless the Company has guaranteed obligations of the joint venture or is otherwise committed to provide further&#13;financial support for the joint venture. If the joint venture subsequently reports net income, the Company will resume applying&#13;the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity&#13;method was suspended.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Long-Lived Assets&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#151;&#13;The Company follows ASC 360-10,&amp;#160;&lt;/font&gt;Property, Plant, and Equipment,&amp;#160;&lt;font style="font-style: normal"&gt;which established&#13;a &amp;#147;primary asset&amp;#148; approach to determine the cash flow estimation period for a group of assets and liabilities that&#13;represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed&#13;for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#13;The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result&#13;from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount&#13;or fair value less cost to sell. For the six months ended June 30, 2015, the Company had not experienced impairment losses on its&#13;long-lived assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&amp;#160;The&#13;Company applies the provisions of ASC 820-10,&amp;#160;&lt;/font&gt;Fair Value Measurements and Disclosures&amp;#160;&lt;font style="font-style: normal"&gt;(&amp;#147;ASC&#13;820-10&amp;#148;)&lt;/font&gt;.&lt;font style="font-style: normal"&gt;&amp;#160;ASC 820-10 defines fair value, and establishes a three-level&#13;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. For&#13;certain financial instruments, including cash and cash equivalents, grants receivable, prepaid expenses, accounts payable and accrued&#13;expenses, the carrying amounts approximate fair value due to their relatively short maturities. The carrying amount of senior secured&#13;convertible debentures approximated fair value as the interest rate charged on the debentures was based on the prevailing rate.&#13;The three levels of valuation hierarchy are defined as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company analyzes all financial instruments with features of both liabilities and equity under ASC 480,&amp;#160;&lt;/font&gt;Distinguishing&#13;Liabilities From Equity,&amp;#160;&lt;font style="font-style: normal"&gt;and ASC 815,&amp;#160;&lt;/font&gt;Derivatives and Hedging.&lt;font style="font-style: normal"&gt;&amp;#160;Derivative&#13;liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded&#13;in results of operations as adjustments to fair value of derivatives. The effects of interactions between embedded derivatives&#13;are calculated and accounted for in arriving at the overall fair value of the financial instruments. In addition, the fair values&#13;of freestanding derivative instruments such as warrant derivatives are valued using the Black-Scholes model.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company uses Level 3 inputs for its valuation methodology for the fair value of certain embedded conversion options and other warrant&#13;derivative liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;The expected volatility of the Company&amp;#146;s common stock is estimated from the historical volatility of daily returns in the Company&amp;#146;s common stock price. The Company monitors the volatility of its common stock on a quarterly basis to observe trends that may impact the fair value of the notes.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 120%; font-style: italic"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;The discount for illiquidity is measured using an average-strike option that calculates the discount as the opportunity cost for not being able to sell a large block of the Company&amp;#146;s common stock immediately at prevailing observable market prices. Inputs to the average-strike option model include the expected volatility of the Company&amp;#146;s common stock and time to sell a large block of the Company&amp;#146;s stock as Level 3 inputs and other observable inputs. The time to sell the stock is estimated considering the historical daily trading volume of our common stock and market maker estimates of the amount of shares that can be offered for sale above the daily trading volume without depressing the price of the Company&amp;#146;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;At&#13;June 30, 2015, the Company identified the following assets and liabilities that are required to be presented on the balance sheet&#13;at fair value:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;As of&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value Measurements at&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30, 2015&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Using Fair Value Hierarchy&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 38%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant overallotment liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;following tables reconcile the change in fair value for measurements categorized within Level 3 of the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 85%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;16,255&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Addition of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,140,771&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total change in fair value for the period included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(329,509)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant Overallotment Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 85%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Addition of warrant overallotment liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;628,767&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total change in fair value for the period included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(14,232)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-style: normal"&gt;Gains included in&#13;earnings for the six months ended June 30, 2015 are reported as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Adjustments to fair value of derivatives&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic; width: 85%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total gain included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic; width: 1%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic; width: 12%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;343,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-style: normal"&gt;The following table&#13;provides quantitative information about measurements categorized within Level 3 of the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 30%; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 11%; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value at&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 33%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 10%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Valuation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic; text-indent: -10pt"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Technique&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Unobservable Input&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant derivative liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Black Scholes Model&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected volatility of the Company's common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45% - 93%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;For&#13;the three and six months ended June 30, 2015, the Company recognized gains of $337,738 and $343,741, respectively, for the changes&#13;in the valuation of derivative liabilities. For the three and six months ended June 30, 2014, the Company recognized gains of $389,771&#13;and $676,800, respectively, for the changes in the valuation of derivative liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company did not identify any non-recurring assets and liabilities that were recorded at fair value during the periods presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;b&gt;and&#13;Deferred Revenue&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&lt;/font&gt;&lt;/b&gt;&amp;#160;The Company&amp;#146;s revenues are primarily generated&#13;from license and research agreements with collaborators. Licensing revenue is recognized on a straight-line basis over the shorter&#13;of the life of the license or the estimated economic life of the patents related to the license.&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;License&#13;fee revenue begins to be recognized in the first full month following the effective date of the license agreement. Deferred revenue&#13;represents the portion of the license and other payments received that has not been earned. Costs associated with license revenue&#13;are deferred and recognized over the same term as the revenue. Reimbursements of research expense pursuant to grants are recorded&#13;in the period during which collection of the reimbursement becomes assured, because the reimbursements are subject to approval.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In&#13;some cases, the Company is entitled to receive royalty payments from licensees. In such cases, the Company recognizes the royalties&#13;when they are earned and collectability of those royalty payments is reasonably assured.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In&#13;connection with its license agreements, the Company recorded $39,468 and $78,936 in license fee revenue for the three and six months&#13;ended June 30, 2015, respectively, in its consolidated statements of operations, and recorded $39,469 and $78,937 in license fee&#13;revenue for the three and six months ended June 30, 2014, respectively. The remainder of the license fees are included in deferred&#13;revenue at June 30, 2015 and December 31, 2014, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses&#13;consist of (i)&amp;#160;employee-related expenses, including salaries, benefits, travel and stock compensation expense; (ii)&amp;#160;external&#13;research and development expenses incurred under arrangements with third parties, such as contract research organizations, investigational&#13;sites and consultants; (iii)&amp;#160;the cost of acquiring, developing and manufacturing clinical study materials; (iv)&amp;#160;facilities&#13;and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other&#13;supplies; and (v)&amp;#160;costs associated with pre-clinical and clinical activities and regulatory operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company enters into consulting, research and other agreements with commercial firms, researchers, universities and others for the&#13;provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other&#13;basis. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred&#13;based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided&#13;to us by the Company&amp;#146;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific&#13;projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Reimbursements of research&#13;expense pursuant to grants are recorded in the period during which collection of the reimbursement becomes assured, because the&#13;reimbursements are subject to approval.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In&#13;certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received&#13;in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are&#13;expensed when the activity has been performed or when the goods have been received.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock Compensation&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company records stock compensation in accordance with ASC 718,&amp;#160;&lt;/font&gt;Compensation &amp;#150; Stock Compensation&amp;#160;&lt;font style="font-style: normal"&gt;(&amp;#147;ASC&#13;718&amp;#148;). ASC 718 requires companies to measure compensation cost for stock employee compensation at fair value at the measurement&#13;date (generally the grant date) and recognize the expense over the employee&amp;#146;s requisite service period. The Company recognizes&#13;in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees&#13;and non-employees.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary&#13;differences and operating loss and tax credit carryforwards, and deferred tax liabilities are recognized for taxable temporary&#13;differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.&#13;Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than&#13;not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted&#13;for the effects of the changes in tax laws and rates at the date of enactment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;When&#13;tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities,&#13;while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately&#13;sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on the weight&#13;of available evidence, management believes it is more likely than not that the position will be sustained upon examination, including&#13;the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.&#13;Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is&#13;more than 50&amp;#160;percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits&#13;associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized&#13;tax benefits in the balance sheets along with any associated interest and penalties that would be payable to the taxing authorities&#13;upon examination.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Applicable&#13;interest and penalties associated with unrecognized tax benefits are classified as additional income taxes in the statements of&#13;operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Basic net loss per share applicable to common stockholders is calculated by dividing net loss applicable to common stockholders&#13;by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss&#13;per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding&#13;for the period, determined using the treasury-stock method and the if-converted method. For purposes of the diluted net loss per&#13;share calculation, convertible preferred stock, stock options, unvested restricted stock, and warrants are considered to be common&#13;stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive&#13;for all periods presented. Therefore, basic and diluted net loss per share was the same for all periods presented. Additionally,&#13;dividends associated with the preferred stock, all of which has been extinguished as of June 30, 2015, has been added back in order&#13;to calculate the net loss applicable to common stockholders.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;At&#13;June 30, 2015 and 2014, approximately 5,834,337 and 1,330,357 potentially dilutive shares, respectively, were excluded from the&#13;shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic&#13;606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard&#13;requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration&#13;that the company expects to receive for those goods or services. In July 2015, the FASB voted to approve a one-year deferral of&#13;the effective date of ASU No. 2014-09. The new standard will now be effective for the Company on January 1, 2018. The Company is&#13;currently evaluating the potential impact that Topic 606 may have on its financial position and results of operations and its method&#13;of adoption.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;On&#13;December 1, 2008, the Company and CHA Bio &amp;#38; Diostech Co., Ltd. (&amp;#147;CHA&amp;#148;) formed an international joint venture. The&#13;new company, Stem Cell &amp;#38; Regenerative Medicine International, Inc. (&amp;#147;SCRMI&amp;#148;), will work towards developing human&#13;blood cells and other clinical therapies based on the Company&amp;#146;s hemangioblast program. As of June 30, 2015, the Company holds&#13;a 40% interest in the joint venture and CHA owns a 60% interest. Additionally, SCRMI has paid the Company a fee of $500,000 for&#13;an exclusive, worldwide license to the hemangioblast program. The Company recorded $7,353 and $14,706 in license fee revenue for&#13;the three and six months ended June 30, 2015, respectively, in its accompanying consolidated statements of operations, and recorded&#13;$7,353 and $14,706 in license fee revenue for the three and six months ended June 30, 2014, respectively. The balance of unamortized&#13;license fee of $307,598 and $322,304 is included in deferred revenue in the accompanying consolidated balance sheets at June 30,&#13;2015 and December 31, 2014, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Property&#13;and equipment consisted of the following at June 30, 2015 and December 31, 2014:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Machinery &amp;#38; equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,305,078&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,186,232&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;104,857&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;104,857&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Office furniture&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;54,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;54,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;620,252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;620,252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Capital leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;68,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,152,923&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,965,567&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(1,264,428&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(1,132,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;888,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;832,963&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Depreciation&#13;expense for the three and six months ended June 30, 2015 amounted to $67,680 and $132,824, respectively. Depreciation expense for&#13;the three and six months ended June 30, 2014 amounted to $33,382 and $64,342, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;accrued settlement is comprised of the following at June 30, 2015 and December 31, 2014:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;SEC Civil Action&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,356,202&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;SEC Section 16 Investigation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;375,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,731,202&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&lt;u&gt;Securities&#13;and Exchange Commission &amp;#150; Civil Action&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In&#13;May 2012, the Company was named as a defendant in a civil action brought by the Securities and Exchange Commission (the &amp;#147;SEC&amp;#148;)&#13;related to transactions involving the sale and issuance of the Company&amp;#146;s securities. The Securities and Exchange Commission&#13;alleges that Company violated Section 5(a) and 5(c) of the Securities Act of 1933 (the &amp;#147;Securities Act&amp;#148;) because certain&#13;sales of shares to outside organizations, completed in late 2008 and early 2009 under the Company&amp;#146;s former management, resulted&#13;in $3.5 million in proceeds to the Company, were neither registered under the Securities Act nor subject to an exemption from registration&#13;under Section 3(a)(10) of the Securities Act, as amended. In addition, the Company is alleged to have violated Section 13(a) of&#13;the Exchange Act of 1934 because the Company did not disclose the sale and issuance of the shares to the SEC on a timely basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In&#13;December 2013, the Company settled the civil action. Under the terms of the settlement accepted by the SEC, the Company consented&#13;to entry of judgment under which it neither admits nor denies liability and agreed to the disgorgement of $3.5 million in proceeds&#13;from the transactions in question. In addition, the Company will pay approximately $587,000 in pre-judgment interest. The total&#13;amount due, approximately $4.1 million, was paid over six equal quarterly installments. In addition, the settlement permanently&#13;restrains and enjoins the Company from violations of Sections 5(a) and 5(c) of the Securities Act, Section 13(a) of the Exchange&#13;Act and Rule 13a-11 under the Exchange Act. As of June 30, 2015, the Company has paid in full its obligation to the SEC.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&lt;u&gt;Securities&#13;and Exchange Commission &amp;#150; Section 16 Investigation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In&#13;April 2013, it was determined that Gary Rabin, the Company&amp;#146;s former Chief Executive Officer, failed to report 27 transactions&#13;in a timely manner on Form 4 under Section 16 of the Exchange Act in which Mr. Rabin sold shares of the Company&amp;#146;s common&#13;stock that took place between February 7, 2011 and January 10, 2013. The SEC then investigated the unreported transactions involving&#13;sales of shares of the Company&amp;#146;s common stock. In September 2014, the Company settled the SEC action arising from the SEC&amp;#146;s&#13;investigation. Under the terms of the settlement accepted by the SEC, the Company consented to the entry of order under which&#13;it neither admits nor denies liability and has agreed to pay a civil penalty of $375,000, which has been previously accrued for,&#13;by July 2015. In addition, the settlement requires the Company to engage an independent Section 16 compliance consultant, provide&#13;Section 16(a) training to each Section 16(a) reporting person, and provide a certification of compliance that each of the preceding&#13;requirements were completed. The settlement also requires the Company to cease and desist from committing or causing any violations&#13;and any future violations of Section 17(a)(2) of the Securities Act, Sections 13(a) and 14(a) of the Exchange Act, and Rules 12b-20,&#13;13a-1, and 14a-9 thereunder. The terms of this settlement require the Company to allocate financial and management resources to&#13;complying with the settlement&amp;#146;s terms, which may have adverse effect on our business. Also, if the SEC deems the Company&#13;to not have complied with any portion of the settlement, it may issue additional fines or sanctions against us which may limit&#13;our ability to issue securities or otherwise conduct our business as currently conducted. As of June 30, 2015 the Company has&#13;paid in full its obligation to the SEC.&lt;/font&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <OCAT:ConvertiblePromissorynotesTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;CAMOFI Senior Secured Convertible&#13;Debentures&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;On&#13;January 11, 2013, the Company entered into a settlement agreement and mutual release (&amp;#147;the Settlement Agreement&amp;#148;) with&#13;CAMOFI Master LDC (&amp;#147;CAMOFI&amp;#148;) and CAMHZN Master LDC (&amp;#147;CAMHZN&amp;#148; and together with CAMOFI, the &amp;#147;CAMOFI&#13;Parties&amp;#148;), relating to the lawsuit between the CAMOFI Parties, as plaintiffs, and the Company, as defendant, in the Supreme&#13;Court of New York. Pursuant to the Settlement Agreement, the Company issued Debentures in the principal amount of $4,732,781 and&#13;$1,267,219 to CAMOFI and CAMHZN, respectively (together the &amp;#147;Debentures&amp;#148;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Debentures had contained an embedded beneficial conversion feature as the Debentures are convertible at a price per share of common&#13;stock equal to 80% of VWAP of the ten consecutive trading days prior to the conversion date. The embedded beneficial conversion&#13;feature was modeled using a binomial lattice model, and had a calculated value at June 30, 2014 of $0. The Company recorded a gain&#13;of $663,000 for the change in the fair value of the embedded conversion option liability for the six months ended June 30, 2014&#13;in connection with the retirement of the remaining debentures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company recorded a debt discount of $725,000, which was being amortized over the life of the Debentures using the effective interest&#13;rate of 22.9%. The unamortized discount balance of $108,229 was written off to interest expense with the retirement of the remaining&#13;outstanding Debentures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;On&#13;May 2, 2014, the Company paid to the CAMOFI Parties an aggregate amount of approximately $1,616,000 calculated in accordance with&#13;the payment acceleration provisions of the Debentures and satisfying the Company&amp;#146;s obligations under the Debentures. The&#13;payment represented the remaining $1,200,000 in principal amount due and an additional amount of approximately $416,000, which&#13;represented penalties, interest and legal cost reimbursement to the CAMOFI Parties. With the payment, the Company satisfied in&#13;full its obligations under the Debentures and the terms of the Settlement Agreement and Mutual Release dated as of December 31,&#13;2012 pursuant to which the Debentures were issued in January 2013. The Company received correspondence from the CAMOFI Parties&#13;stating that the CAMOFI Parties believe the aggregate amount due to be different than the amount the Company paid. The Company&#13;believes that its interpretation of the Debentures is accurate and complete and its liability under the Debentures is zero as of&#13;June 30, 2015.&lt;/font&gt;&lt;/p&gt;</OCAT:ConvertiblePromissorynotesTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Warrant Activity&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of warrant activity for the six months ended June 30, 2015 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 33%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number&amp;#160;of&lt;br /&gt;&#13; Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number&amp;#160;of&lt;br /&gt;&#13; Common Shares&lt;br /&gt;&#13; Underlying&lt;br /&gt;&#13; Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;br /&gt;&#13; Average &lt;br /&gt;&#13;Exercise &lt;br /&gt;&#13;Price $&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Remaining&lt;br /&gt;&#13; Contractual &lt;br /&gt;&#13;Life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Aggregate&lt;br /&gt;&#13; Intrinsic &lt;br /&gt;&#13;Value (000)$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;40.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5,985,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,992,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6,030,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,038,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Exercisable, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;40.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;0.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The aggregate intrinsic&#13;value in the table above is before applicable income taxes and is calculated based on the difference between the exercise price&#13;of the warrants and the quoted price of the Company&amp;#146;s common stock as of the reporting date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;On June&amp;#160;16, 2015,&#13;the Company entered into an underwriting agreement (the &amp;#147;Underwriting Agreement&amp;#148;) related to a registered direct offering&#13;(the &amp;#147;Offering&amp;#148;) of an aggregate of 5,500,000 shares of common stock, par value $0.001 per share (the &amp;#147;Shares&amp;#148;),&#13;together with accompanying warrants to purchase an aggregate of 2,750,000 shares of common stock (the &amp;#147;Warrants&amp;#148;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The Shares and Warrants&#13;were sold in combination, with one Warrant to purchase one half of one share of common stock, for each Share sold. The combined&#13;sale price to the public for each Share and accompanying Warrant was $5.50. The per share proceeds received by the Company from&#13;the underwriters, after accounting for the standard 6% underwriting fee, for the Shares and accompanying Warrants was $5.17. The&#13;Offering closed on June 22, 2015 and the aggregate net proceeds from the sale of the Shares and accompanying Warrants, excluding&#13;the potential future proceeds, if any, from the exercise of the Warrants issued in the offering, was approximately $28.2 million&#13;after deducting the underwriting discount of $1,815,000 and estimated offering expenses payable by the Company of approximately&#13;$170,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The Warrants may be&#13;exercised at any time after December&amp;#160;22, 2015 until December&amp;#160;22, 2020. The initial exercise price for the Warrants will&#13;be $7.48 subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications&#13;or similar events affecting the Company&amp;#146;s common stock. The Warrants are classified as a liability on the balance sheet as&#13;of June 30, 2015 due to the fact that at inception, the Warrants embody an obligation to repurchase the Warrants in the event of&#13;a change in control whereby the surviving entity is not listed on a public exchange. Because of this potential settlement, regardless&#13;of probability, and the fact that the choice of cash settlement may ultimately lie with the warrant holders, triggers liability&#13;classification for the warrants under ASC 480. At inception, the fair value of the warrants was $10,237,968.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In addition, the Underwriting&#13;Agreement provides the underwriters a 30-day option to purchase up to an additional 825,000 shares and/or warrants to purchase&#13;an additional 412,500 shares of common stock from the Company (of which 485,000 Warrants representing 242,500 shares of common&#13;stock were purchased immediately in connection with the Offering&amp;#146;s closing on June 22, 2015).&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;On&#13;September 19, 2012 the Company entered into a purchase agreement with Lincoln Park Capital, LLC (&amp;#147;Lincoln Park&amp;#148;). Pursuant&#13;to the purchase agreement, the Company had the right to sell to Lincoln Park up to $35,000,000 in shares of its common stock. On&#13;June 18, 2014, the Company completed the last sale of common stock to Lincoln Park under this agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;On&#13;June 27, 2014, the Company entered into a similar purchase agreement, the &amp;#147;2014 Purchase Agreement,&amp;#148; with Lincoln Park&#13;pursuant to which the Company has the right to sell to Lincoln Park up to $30,000,000 in shares of its common stock, subject to&#13;certain limitations set forth in the purchase agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;During&#13;the six months ended June 30, 2015, Lincoln Park purchased 2,022,996 shares of common stock pursuant to the 2014 Purchase Agreement&#13;for cash proceeds of $12,797,047.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;During&#13;the six months ended June 30, 2015, the Company issued various board members 15,000 shares of common stock valued at $85,725 as&#13;compensation for board services.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;At&#13;the annual meeting of the Company&amp;#146;s stockholders held in November 2014, the Company&amp;#146;s stockholders approved a Certificate&#13;of Amendment to the Company&amp;#146;s Certificate of Incorporation. The Certificate of Amendment provided for an increase in the&#13;number of authorized shares of the Company&amp;#146;s common stock, par value $0.001 per share, from 37,500,000 to 60,000,000. The&#13;Certificate of Amendment became effective upon its filing with the Secretary of State of the State of Delaware on November 12,&#13;2014.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;On&#13;June&amp;#160;16, 2015, the Company entered into the Underwriting Agreement related to the Offering. See Note 7, &amp;#147;Warrant Summary,&amp;#148;&#13;for additional information about the Offering.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of stock plans as of June 30, 2015 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock Plans&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options/Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options/Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Available&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Stock Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;For Grant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Authorized&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 38%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2005 Stock Incentive Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,756,356&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,118,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,231,457&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5,818,388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014 Stock Option and Incentive Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;209,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;174,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;41,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,965,356&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,292,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,272,457&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6,068,388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock Option Activity&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of option activity for the six months ended June 30, 2015 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Aggregate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Contractual&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Intrinsic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 36%; padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,245,381&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;12.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;8.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;12,110&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;99,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Forfeited/canceled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(51,450&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;17.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,292,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Vested and expected to vest&amp;#160;at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,173,329&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11.89&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Exercisable, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,372,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;14.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;aggregate intrinsic value in the table above is before applicable income taxes and is calculated based on the difference between&#13;the exercise price of the options and the quoted price of the Company&amp;#146;s common stock as of the reporting date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;assumptions used in calculating the fair value of options granted using the Black-Scholes option pricing model for options granted&#13;during the six months ended, are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 67%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1.59 &amp;#150; 2.07%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;.02 &amp;#150; 2.27%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected life of the options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5.00 - 6.25 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5.00 - 6.25 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;93 - 124%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;112 - 148%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;0%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;0%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;weighted average grant-date fair value for the options granted during the six months ended June 30, 2015 and 2014 was $5.10 and&#13;$7.68, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;unrecognized compensation expense related to the unvested options as of June 30, 2015, was $6,176,415 which will be recognized&#13;over the weighted average vesting period of 2.24 years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Restricted Stock Unit Activity&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of the restricted stock unit activity for the six months ended June 30, 2015:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number of&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Shares&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Underlying Restricted&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Grant-Date&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;per Share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Recognition&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Period&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;(in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;493,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;503,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Unearned stock-based compensation expense of outstanding restricted units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,616,066&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Stock&#13;compensation expense to employees and non-employees for the three and six months ended June 30, 2015 and 2014 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Three Months Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 69%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;537,772&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;90,144&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;G&amp;#38;A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;898,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;179,546&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,436,072&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;269,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Six Months Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 69%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,092,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;175,329&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;G&amp;#38;A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,908,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;533,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,001,426&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;708,760&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;At&#13;the annual meeting of the Company&amp;#146;s stockholders held in July 2015, the Company&amp;#146;s stockholders approved the First Amendment&#13;to the Company&amp;#146;s 2014 Stock Option and Incentive Plan (the &amp;#147;&lt;u&gt;Plan Amendment&lt;/u&gt;&amp;#148;) to, among other things, increase&#13;the number of shares of common stock available for issuance thereunder by 3,750,000 shares to a total of 4,000,000 shares. The&#13;Plan Amendment previously had been approved, subject to stockholder approval, by the Company&amp;#146;s Board of Directors.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company follows accounting standards set by the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;). The accompanying&#13;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#13;States of America, GAAP. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification,&amp;#153;&#13;sometimes referred to as the Codification or &amp;#147;ASC.&amp;#148; Although the Company believes that the disclosures in these financial&#13;statements are adequate to make the information presented not misleading, certain information normally included in the footnotes&#13;prepared in accordance with GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission&#13;(&amp;#147;SEC&amp;#148;).&amp;#160; The accompanying financial statements should be read in conjunction with the audited financial statements&#13;and notes thereto included in the Company&amp;#146;s Annual Report on Form 10&amp;#8722;K for the fiscal year ended December 31, 2014&#13;filed with the SEC on March 16, 2015.&amp;#160; The results for the three and six month periods ended June 30, 2015 are not necessarily&#13;indicative of the results that may be expected for the fiscal year ending December 31, 2015, or any future period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;accompanying consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the&#13;Company as a going concern. Management&amp;#146;s plans to continue as a going concern contemplate raising additional capital including&#13;the execution of an underwritten secondary offering completed in the second quarter of 2015 that resulted in approximately $28.4&#13;million in net proceeds, and the prior execution of an agreement for a $30 million equity line in late June 2014, of which approximately&#13;$5.8 million remains available as of June 30, 2015. The Company believes that its current cash balance, and the $5,822,405 available&#13;under the Lincoln Park financing arrangement as of June 30, 2015, will be sufficient to fund operations into the second half of&#13;2016. There can be no assurances that management can raise the necessary additional capital on favorable terms or at all. The&#13;accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue&#13;as a going concern.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The accounts of the Company and its wholly-owned subsidiary Mytogen,&amp;#160;Inc. are included in the accompanying consolidated financial&#13;statements. All intercompany balances and transactions were eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Segment Reporting&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;font style="word-spacing: 0px"&gt;&amp;#151;&#13;ASC 280,&amp;#160;&lt;i&gt;Segment Reporting&lt;/i&gt;&amp;#160;&lt;/font&gt;requires use of the &amp;#147;management approach&amp;#148; model for segment reporting.&#13;The management approach model is based on the way a company&amp;#146;s management organizes segments within the company for making&#13;operating decisions and assessing performance. The Company determined it has one operating segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;These consolidated financial statements have been prepared in accordance with GAAP and, accordingly, require management to make&#13;estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and&#13;the reported amounts of revenues and expenses during the reporting period. In addition, management has estimated variables used&#13;to calculate the Black-Scholes option pricing model used to value derivative instruments, including outstanding warrants. Also,&#13;management has estimated the expected economic life and value of the Company&amp;#146;s licensed technology, the Company&amp;#146;s net&#13;operating loss for tax purposes, share-based payments for compensation to employees, directors, consultants and investment banks,&#13;and the useful lives of the Company&amp;#146;s fixed assets. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Certain prior period financial statement balances have been reclassified to conform to the current period presentation. Items include&#13;the presentation of net loss applicable to common stock and net loss applicable to common share on the face of the statement of&#13;operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Cash equivalents are comprised of certain highly liquid investments with maturities of three months or less when purchased. The&#13;Company maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. The Company has not experienced&#13;any losses related to this concentration of risk. As of June 30, 2015 and December 31, 2014, the Company had deposits in excess&#13;of federally-insured limits totaling $31,601,475 and $4,325,886, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Commitments and Contingencies&amp;#160;&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#151;&#13;The Company recognizes liabilities for contingencies and commitments when a loss is probable and can be reasonably estimated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Relating&#13;to loss contingencies the Company accrues the best estimate of a loss within a range. If no estimate in a range is better than&#13;any other, the minimum amount is accrued. The Company discloses a reasonably possible loss in excess of the amount accrued, if&#13;applicable. For reasonably possible loss contingencies, the Company discloses the nature of the loss contingency and provides a&#13;range of the estimate of possible loss or state that an estimate cannot be made.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Included&#13;in the other liabilities balance as of December 31, 2014 is approximately $1,200,000, primarily related to the acquisition of Mytogen&#13;which the Company did not expect to settle during 2015. This balance was reclassified to the accounts payable balance as of June&#13;30, 2015 as the Company expects to settle within the coming year.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <OCAT:GrantsReceivablePolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Grants Receivable&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company periodically assesses its grants receivable for collectability on a specific identification basis. If collectability&#13;of an account becomes unlikely, the Company records an allowance for that doubtful account. Once the Company has exhausted efforts&#13;to collect, management writes off the grants receivable against the allowance it has already created.&lt;/font&gt;&lt;/p&gt;</OCAT:GrantsReceivablePolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company records its property and equipment at historical cost. The Company expenses maintenance and repairs as incurred. Upon&#13;disposition of property and equipment, the gross cost and accumulated depreciation are written off and the difference between the&#13;proceeds and the net book value is recorded as a gain or loss on sale of assets. In the case of certain assets acquired under capital&#13;leases, the assets are recorded net of imputed interest, based upon the net present value of future payments. Assets under capital&#13;lease are pledged as collateral for the related lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company provides for depreciation over the assets&amp;#146; estimated useful lives as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 30%; text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Machinery &amp;#38; equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 69%; text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Office furniture&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Lesser of remaining lease life or economic life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Capital leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Lesser of lease life or economic life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company follows ASC 350-30,&amp;#160;&lt;/font&gt;General Intangibles Other than Goodwill&amp;#160;&lt;font style="font-style: normal"&gt;(&amp;#147;ASC&#13;350-30&amp;#148;), in accounting for its patents. ASC 350-30 provides that costs of internally developing, maintaining, or restoring&#13;intangible assets that are not specifically identifiable, that have indeterminate lives, or that are inherent in a continuing business&#13;and related to an entity as a whole, shall be recognized as an expense when incurred. The Company has expensed as research and&#13;development expense all costs associated with developing its patents.&lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Equity Method Investment&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company follows ASC 323,&amp;#160;&lt;/font&gt;Investments-Equity Method and Joint Ventures,&amp;#160;&lt;font style="font-style: normal"&gt;in&#13;accounting for its investment in the joint venture. In the event the Company&amp;#146;s share of the joint venture&amp;#146;s net losses&#13;reduces the Company&amp;#146;s investment to zero, the Company will discontinue applying the equity method and will not provide for&#13;additional losses unless the Company has guaranteed obligations of the joint venture or is otherwise committed to provide further&#13;financial support for the joint venture. If the joint venture subsequently reports net income, the Company will resume applying&#13;the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity&#13;method was suspended.&lt;/font&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <OCAT:LonglivedAssetsPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Long-Lived Assets&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#151;&#13;The Company follows ASC 360-10,&amp;#160;&lt;/font&gt;Property, Plant, and Equipment,&amp;#160;&lt;font style="font-style: normal"&gt;which established&#13;a &amp;#147;primary asset&amp;#148; approach to determine the cash flow estimation period for a group of assets and liabilities that&#13;represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed&#13;for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#13;The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result&#13;from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount&#13;or fair value less cost to sell. For the six months ended June 30, 2015, the Company had not experienced impairment losses on its&#13;long-lived assets.&lt;/font&gt;&lt;/p&gt;</OCAT:LonglivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&amp;#160;The&#13;Company applies the provisions of ASC 820-10,&amp;#160;&lt;/font&gt;Fair Value Measurements and Disclosures&amp;#160;&lt;font style="font-style: normal"&gt;(&amp;#147;ASC&#13;820-10&amp;#148;)&lt;/font&gt;.&lt;font style="font-style: normal"&gt;&amp;#160;ASC 820-10 defines fair value, and establishes a three-level&#13;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. For&#13;certain financial instruments, including cash and cash equivalents, grants receivable, prepaid expenses, accounts payable and accrued&#13;expenses, the carrying amounts approximate fair value due to their relatively short maturities. The carrying amount of senior secured&#13;convertible debentures approximated fair value as the interest rate charged on the debentures was based on the prevailing rate.&#13;The three levels of valuation hierarchy are defined as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company analyzes all financial instruments with features of both liabilities and equity under ASC 480,&amp;#160;&lt;/font&gt;Distinguishing&#13;Liabilities From Equity,&amp;#160;&lt;font style="font-style: normal"&gt;and ASC 815,&amp;#160;&lt;/font&gt;Derivatives and Hedging.&lt;font style="font-style: normal"&gt;&amp;#160;Derivative&#13;liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded&#13;in results of operations as adjustments to fair value of derivatives. The effects of interactions between embedded derivatives&#13;are calculated and accounted for in arriving at the overall fair value of the financial instruments. In addition, the fair values&#13;of freestanding derivative instruments such as warrant derivatives are valued using the Black-Scholes model.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company uses Level 3 inputs for its valuation methodology for the fair value of certain embedded conversion options and other warrant&#13;derivative liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#149;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;The expected volatility of the Company&amp;#146;s common stock is estimated from the historical volatility of daily returns in the Company&amp;#146;s common stock price. The Company monitors the volatility of its common stock on a quarterly basis to observe trends that may impact the fair value of the notes.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;The discount for illiquidity is measured using an average-strike option that calculates the discount as the opportunity cost for not being able to sell a large block of the Company&amp;#146;s common stock immediately at prevailing observable market prices. Inputs to the average-strike option model include the expected volatility of the Company&amp;#146;s common stock and time to sell a large block of the Company&amp;#146;s stock as Level 3 inputs and other observable inputs. The time to sell the stock is estimated considering the historical daily trading volume of our common stock and market maker estimates of the amount of shares that can be offered for sale above the daily trading volume without depressing the price of the Company&amp;#146;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;At&#13;June 30, 2015, the Company identified the following assets and liabilities that are required to be presented on the balance sheet&#13;at fair value:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;As of&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value Measurements at&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30, 2015&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Using Fair Value Hierarchy&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 38%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant overallotment liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 100%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;9&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;following tables reconcile the change in fair value for measurements categorized within Level 3 of the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 85%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;16,255&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Addition of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,140,771&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total change in fair value for the period included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(329,509)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant Overallotment Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 83%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Addition of warrant overallotment liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;628,767&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total change in fair value for the period included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(14,232)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Gains&#13;included in earnings for the six months ended June 30, 2015 are reported as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Adjustments to fair value of derivatives&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif; width: 83%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total gain included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right; width: 14%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;343,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-style: normal"&gt;The following table&#13;provides quantitative information about measurements categorized within Level 3 of the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 30%; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 11%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value at&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 33%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 10%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Valuation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center; text-indent: -10pt"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Technique&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Unobservable Input&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant derivative liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Black Scholes Model&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected volatility of the Company's common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45% - 93%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;For&#13;the three and six months ended June 30, 2015, the Company recognized gains of $337,738 and $343,741, respectively, for the changes&#13;in the valuation of derivative liabilities. For the three and six months ended June 30, 2014, the Company recognized gains of $389,771&#13;and $676,800, respectively, for the changes in the valuation of derivative liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company did not identify any non-recurring assets and liabilities that were recorded at fair value during the periods presented.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;b&gt;&lt;i&gt;and Deferred Revenue&lt;/i&gt;&amp;#160;&amp;#151;&lt;/b&gt;&amp;#160;The&#13;Company&amp;#146;s revenues are primarily generated from license and research agreements with collaborators. Licensing revenue is&#13;recognized on a straight-line basis over the shorter of the life of the license or the estimated economic life of the patents related&#13;to the license.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-indent: 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"&gt;License fee revenue begins to be recognized in&#13;the first full month following the effective date of the license agreement. Deferred revenue represents the portion of the license&#13;and other payments received that has not been earned. Costs associated with license revenue are deferred and recognized over the&#13;same term as the revenue. Reimbursements of research expense pursuant to grants are recorded in the period during which collection&#13;of the reimbursement becomes assured, because the reimbursements are subject to approval.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-indent: 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"&gt;In some cases, the Company is entitled to receive&#13;royalty payments from licensees. In such cases, the Company recognizes the royalties when they are earned and collectability of&#13;those royalty payments is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-indent: 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"&gt;In connection with its license agreements, the&#13;Company recorded $39,468 and $78,936 in license fee revenue for the three and six months ended June 30, 2015, respectively, in&#13;its consolidated statements of operations, and recorded $39,469 and $78,937 in license fee revenue for the three and six months&#13;ended June 30, 2014, respectively. The remainder of the license fees are included in deferred revenue at June 30, 2015 and December&#13;31, 2014, respectively.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses&#13;consist of (i)&amp;#160;employee-related expenses, including salaries, benefits, travel and stock compensation expense; (ii)&amp;#160;external&#13;research and development expenses incurred under arrangements with third parties, such as contract research organizations, investigational&#13;sites and consultants; (iii)&amp;#160;the cost of acquiring, developing and manufacturing clinical study materials; (iv)&amp;#160;facilities&#13;and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other&#13;supplies; and (v)&amp;#160;costs associated with pre-clinical and clinical activities and regulatory operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company enters into consulting, research and other agreements with commercial firms, researchers, universities and others for the&#13;provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other&#13;basis. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred&#13;based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided&#13;to us by the Company&amp;#146;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific&#13;projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Reimbursements of research&#13;expense pursuant to grants are recorded in the period during which collection of the reimbursement becomes assured, because the&#13;reimbursements are subject to approval.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;In&#13;certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received&#13;in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are&#13;expensed when the activity has been performed or when the goods have been received.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock Compensation&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;The Company records stock compensation in accordance with ASC 718,&amp;#160;&lt;/font&gt;Compensation &amp;#150; Stock Compensation&amp;#160;&lt;font style="font-style: normal"&gt;(&amp;#147;ASC&#13;718&amp;#148;). ASC 718 requires companies to measure compensation cost for stock employee compensation at fair value at the measurement&#13;date (generally the grant date) and recognize the expense over the employee&amp;#146;s requisite service period. The Company recognizes&#13;in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees&#13;and non-employees.&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary&#13;differences and operating loss and tax credit carryforwards, and deferred tax liabilities are recognized for taxable temporary&#13;differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.&#13;Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than&#13;not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted&#13;for the effects of the changes in tax laws and rates at the date of enactment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;When&#13;tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities,&#13;while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately&#13;sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on the weight&#13;of available evidence, management believes it is more likely than not that the position will be sustained upon examination, including&#13;the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.&#13;Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is&#13;more than 50&amp;#160;percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits&#13;associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized&#13;tax benefits in the balance sheets along with any associated interest and penalties that would be payable to the taxing authorities&#13;upon examination.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Applicable&#13;interest and penalties associated with unrecognized tax benefits are classified as additional income taxes in the statements of&#13;operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;Basic net loss per share applicable to common stockholders is calculated by dividing net loss applicable to common stockholders&#13;by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss&#13;per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding&#13;for the period, determined using the treasury-stock method and the if-converted method. For purposes of the diluted net loss per&#13;share calculation, convertible preferred stock, stock options, unvested restricted stock, and warrants are considered to be common&#13;stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive&#13;for all periods presented. Therefore, basic and diluted net loss per share was the same for all periods presented. Additionally,&#13;dividends associated with the preferred stock, all of which has been extinguished as of June 30, 2015, has been added back in order&#13;to calculate the net loss applicable to common stockholders.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;At&#13;June 30, 2015 and 2014, approximately 5,834,337 and 1,330,357 potentially dilutive shares, respectively, were excluded from the&#13;shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#151;&#13;In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic&#13;606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard&#13;requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration&#13;that the company expects to receive for those goods or services. In July 2015, the FASB voted to approve a one-year deferral of&#13;the effective date of ASU No. 2014-09. The new standard will now be effective for the Company on January 1, 2018. The Company is&#13;currently evaluating the potential impact that Topic 606 may have on its financial position and results of operations and its method&#13;of adoption.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;At&#13;June 30, 2015, the Company identified the following assets and liabilities that are required to be presented on the balance sheet&#13;at fair value:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;As of&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value Measurements at&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30, 2015&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Using Fair Value Hierarchy&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 38%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant overallotment liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;following tables reconcile the change in fair value for measurements categorized within Level 3 of the fair value hierarchy:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 85%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;16,255&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Addition of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11,140,771&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total change in fair value for the period included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(329,509)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,827,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant Overallotment Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 85%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Addition of warrant overallotment liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;628,767&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total change in fair value for the period included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(14,232)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Balance at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;614,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-style: normal"&gt;Gains included in&#13;earnings for the six months ended June 30, 2015 are reported as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 120%; font-style: italic"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Adjustments to fair value of derivatives&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 120%; font-style: italic; width: 85%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total gain included in earnings&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 120%; font-style: italic; width: 1%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 120%; font-style: italic; width: 12%"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;343,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 120%; font-style: italic"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock>
    <us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The&#13;following table provides quantitative information about measurements categorized within Level 3 of the fair value hierarchy:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 30%; text-indent: -10pt; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 11%; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value at&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 12%; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 33%; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 10%; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Valuation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="background-color: white; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt/120% Times New Roman, Times, Serif; text-align: center; text-indent: -10pt"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt/120% Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt/120% Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Technique&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt/120% Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Unobservable Input&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt/120% Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Warrant derivative liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: center; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$11,442,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Black Scholes Model&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected volatility of the Company's common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; font: italic 8pt/120% Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45% - 93%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Property&#13;and equipment consisted of the following at June 30, 2015 and December 31, 2014:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Machinery &amp;#38; equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,305,078&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,186,232&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;104,857&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;104,857&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Office furniture&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;54,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;54,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;620,252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;620,252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Capital leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;68,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,152,923&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,965,567&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(1,264,428&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(1,132,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;888,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;832,963&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <OCAT:AccruedSettlementTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;accrued settlement is comprised of the following at June 30, 2015 and December 31, 2014:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;SEC Civil Action&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,356,202&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;SEC Section 16 Investigation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;375,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,731,202&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OCAT:AccruedSettlementTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of warrant activity for the six months ended June 30, 2015 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 33%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number&amp;#160;of Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number&amp;#160;of Common Shares Underlying Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted Average Exercise Price $&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted Average Remaining Contractual Life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Aggregate Intrinsic Value (000)$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;40.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5,985,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,992,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6,030,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,038,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Exercisable, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;45,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;40.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;0.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <OCAT:StockPlansTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of stock plans as of June 30, 2015 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options/Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options/Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Available&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Stock Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;For Grant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Authorized&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 38%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2005 Stock Incentive Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,756,356&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,118,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,231,457&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5,818,388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014 Stock Option and Incentive Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;209,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;174,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;41,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,965,356&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,292,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,272,457&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6,068,388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OCAT:StockPlansTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of option activity for the six months ended June 30, 2015 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Aggregate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Contractual&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Intrinsic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 36%; padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,245,381&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;12.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;8.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;12,110&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;99,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Forfeited/canceled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;(51,450&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;17.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,292,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Vested and expected to vest&amp;#160;at June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,173,329&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;11.89&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Exercisable, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,372,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;14.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;The&#13;assumptions used in calculating the fair value of options granted using the Black-Scholes option pricing model for options granted&#13;during the six months ended, are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 67%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1.59 &amp;#150; 2.07%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;.02 &amp;#150; 2.27%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected life of the options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5.00 - 6.25 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;5.00 - 6.25 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;93 - 124%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;112 - 148%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;0%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;0%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;A&#13;summary of the restricted stock unit activity for the six months ended June 30, 2015:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Number of&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Shares&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Underlying Restricted&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Grant-Date&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Fair Value&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;per Share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Recognition&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;Period&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt; font-style: normal"&gt;(in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;493,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;10,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;6.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Outstanding, June 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;503,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;7.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Unearned stock-based compensation expense of outstanding restricted units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2,616,066&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-style: normal"&gt;Stock&#13;compensation expense to employees and non-employees for the three and six months ended June 30, 2015 and 2014 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Three Months Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 69%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;537,772&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;90,144&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;G&amp;#38;A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;898,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;179,546&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,436,072&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;269,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;font style="font-style: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Six Months Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;June 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 69%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,092,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;175,329&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;G&amp;#38;A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;1,908,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;533,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3,001,426&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: italic 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;708,760&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <OCAT:IssuanceOfCommonStockInFinancingArrangementValue contextRef="From2015-01-01to2015-06-30_custom_LincolnParkMember" unitRef="USD" decimals="0">12797047</OCAT:IssuanceOfCommonStockInFinancingArrangementValue>
    <OCAT:IssuanceOfCommonStockInFinancingArrangementValue contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">30201463</OCAT:IssuanceOfCommonStockInFinancingArrangementValue>
    <OCAT:IssuanceOfCommonStockInFinancingArrangementValue contextRef="From2015-01-01to2015-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7523</OCAT:IssuanceOfCommonStockInFinancingArrangementValue>
    <OCAT:IssuanceOfCommonStockInFinancingArrangementValue contextRef="From2015-01-01to2015-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">30193940</OCAT:IssuanceOfCommonStockInFinancingArrangementValue>
    <OCAT:IssuanceOfCommonStockInFinancingArrangementShares contextRef="From2015-01-01to2015-06-30_custom_LincolnParkMember" unitRef="Shares" decimals="INF">2022996</OCAT:IssuanceOfCommonStockInFinancingArrangementShares>
    <OCAT:IssuanceOfCommonStockInFinancingArrangementShares contextRef="From2015-01-01to2015-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7522996</OCAT:IssuanceOfCommonStockInFinancingArrangementShares>
    <OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementSharesIssued contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">427373609</OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementSharesIssued>
    <OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementSharesIssued contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</OCAT:IssuanceOfSharesOfCommonStockForAccruedSettlementSharesIssued>
    <OCAT:NumberOfCommonSharesUnderlyingWarrantsBeginning contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">45906</OCAT:NumberOfCommonSharesUnderlyingWarrantsBeginning>
    <OCAT:NumberOfCommonSharesUnderlyingWarrantsBeginning contextRef="AsOf2015-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3038406</OCAT:NumberOfCommonSharesUnderlyingWarrantsBeginning>
    <OCAT:CapitalExpendituresFundedByCapitalLeaseBorrowings contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">0</OCAT:CapitalExpendituresFundedByCapitalLeaseBorrowings>
    <OCAT:CapitalExpendituresFundedByCapitalLeaseBorrowings contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">68510</OCAT:CapitalExpendituresFundedByCapitalLeaseBorrowings>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">-13468547</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-11567009</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DebtIssuanceCosts contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">0</us-gaap:DebtIssuanceCosts>
    <us-gaap:DebtIssuanceCosts contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">904189</us-gaap:DebtIssuanceCosts>
    <us-gaap:DebtIssuanceCosts contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">904189</us-gaap:DebtIssuanceCosts>
    <us-gaap:DebtIssuanceCosts contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">0</us-gaap:DebtIssuanceCosts>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">1200000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">1699</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2015-06-30" unitRef="USD" xsi:nil="true" />
    <OCAT:IssuanceOfSharesOfCommonStockAsCommitmentFinancingFee contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">10606707</OCAT:IssuanceOfSharesOfCommonStockAsCommitmentFinancingFee>
    <OCAT:IssuanceOfSharesOfCommonStockAsCommitmentFinancingFee contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</OCAT:IssuanceOfSharesOfCommonStockAsCommitmentFinancingFee>
    <OCAT:WarrantOverallotmentLiability contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</OCAT:WarrantOverallotmentLiability>
    <OCAT:WarrantOverallotmentLiability contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</OCAT:WarrantOverallotmentLiability>
    <OCAT:WarrantOverallotmentLiability contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</OCAT:WarrantOverallotmentLiability>
    <OCAT:WarrantOverallotmentLiability contextRef="AsOf2015-06-30_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">614535</OCAT:WarrantOverallotmentLiability>
    <OCAT:WarrantOverallotmentLiability contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">614535</OCAT:WarrantOverallotmentLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities>
    <OCAT:NumberOfCommonSharesUnderlyingWarrantsGranted contextRef="From2015-01-01to2015-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2992500</OCAT:NumberOfCommonSharesUnderlyingWarrantsGranted>
    <OCAT:NumberOfCommonSharesUnderlyingWarrantsExercisable contextRef="AsOf2015-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">45906</OCAT:NumberOfCommonSharesUnderlyingWarrantsExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1372916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">11.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">14.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2015-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">8</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2015-06-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">2616066</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">708760</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">175329</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">533431</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1092492</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">1908934</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">3001426</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">1436072</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">269690</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-04-01to2014-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">90144</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-04-01to2015-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">537772</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-04-01to2014-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">179546</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-04-01to2015-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">898300</us-gaap:AllocatedShareBasedCompensationExpense>
    <OCAT:IssuanceOfCommonStockAsCommitmentFinancingFee contextRef="From2014-01-01to2014-06-30" unitRef="USD" decimals="0">698926</OCAT:IssuanceOfCommonStockAsCommitmentFinancingFee>
    <OCAT:IssuanceOfCommonStockAsCommitmentFinancingFee contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">0</OCAT:IssuanceOfCommonStockAsCommitmentFinancingFee>
    <OCAT:EstimatedUsefulLivesTableTextBlock contextRef="From2015-01-01to2015-06-30">&lt;p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-style: normal"&gt;The&#13;Company provides for depreciation over the assets&amp;#146; estimated useful lives as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 30%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Machinery &amp;#38; equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 69%; font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;3 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Office furniture&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Lesser of remaining lease life or economic life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Capital leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: italic 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt; font-style: normal"&gt;Lesser of lease life or economic life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OCAT:EstimatedUsefulLivesTableTextBlock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2015-01-01to2015-06-30" unitRef="USD" decimals="0">2612466</us-gaap:PaymentsOfStockIssuanceCosts>
</xbrli:xbrl>